Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Infection and Immunity logoLink to Infection and Immunity
. 1985 Oct;50(1):22–26. doi: 10.1128/iai.50.1.22-26.1985

Effects of cyclosporine in experimental cryptococcal meningitis.

J R Perfect, D T Durack
PMCID: PMC262129  PMID: 3899932

Abstract

We studied the effects of cyclosporine on experimental cryptococcal meningitis. Like cortisone, cyclosporine depressed the highly effective defense mechanisms of normal rabbits against inoculated Cryptococcus neoformans, causing them to develop progressive, fatal cryptococcal meningitis. Unlike cortisone, which causes a striking reduction in leukocytes in cerebrospinal fluid, cyclosporine depressed mononuclear cell function rather than numbers. Interleukin 2, a primary target for the immunodepressive action of cyclosporine, appears to be of central importance in central nervous system defenses against cryptococci. The findings suggest that humans receiving cyclosporine are likely to suffer increased incidence of cryptococcal infection.

Full text

PDF
22

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borel J. F. Cyclosporin-A--present experimental status. Transplant Proc. 1981 Mar;13(1 Pt 1):344–348. [PubMed] [Google Scholar]
  2. Bueding E., Hawkins J., Cha Y. N. Antischistosomal effects of cyclosporin A. Agents Actions. 1981 Jul;11(4):380–383. doi: 10.1007/BF01982474. [DOI] [PubMed] [Google Scholar]
  3. Bunjes D., Hardt C., Röllinghoff M., Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981 Aug;11(8):657–661. doi: 10.1002/eji.1830110812. [DOI] [PubMed] [Google Scholar]
  4. Cauley L. K., Murphy J. W. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun. 1979 Mar;23(3):644–651. doi: 10.1128/iai.23.3.644-651.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Diamond R. D., Allison A. C. Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect Immun. 1976 Sep;14(3):716–720. doi: 10.1128/iai.14.3.716-720.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Diamond R. D., Bennett J. E. Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J Infect Dis. 1973 Jun;127(6):694–697. doi: 10.1093/infdis/127.6.694. [DOI] [PubMed] [Google Scholar]
  7. Diamond R. D., Bennett J. E. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974 Feb;80(2):176–181. doi: 10.7326/0003-4819-80-2-176. [DOI] [PubMed] [Google Scholar]
  8. Diamond R. D. Effects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosis. Infect Immun. 1977 Jul;17(1):187–194. doi: 10.1128/iai.17.1.187-194.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dummer J. S., Hardy A., Poorsattar A., Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation. 1983 Sep;36(3):259–267. doi: 10.1097/00007890-198309000-00007. [DOI] [PubMed] [Google Scholar]
  10. Gentry L. O., Remington J. S. Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis. 1971 Jan;123(1):22–31. doi: 10.1093/infdis/123.1.22. [DOI] [PubMed] [Google Scholar]
  11. Gillis S. Interleukin 2: biology and biochemistry. J Clin Immunol. 1983 Jan;3(1):1–13. doi: 10.1007/BF00919133. [DOI] [PubMed] [Google Scholar]
  12. Graybill J. R., Alford R. H. Cell-mediated immunity in Cryptococcosis. Cell Immunol. 1974 Oct;14(1):12–21. doi: 10.1016/0008-8749(74)90164-6. [DOI] [PubMed] [Google Scholar]
  13. Graybill J. R., Hague M., Drutz D. J. Passive immunization in murine cryptococcosis. Sabouraudia. 1981 Dec;19(4):237–244. doi: 10.1080/00362178185380411. [DOI] [PubMed] [Google Scholar]
  14. Graybill J. R., Mitchell L., Drutz D. J. Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J Infect Dis. 1979 Oct;140(4):546–552. doi: 10.1093/infdis/140.4.546. [DOI] [PubMed] [Google Scholar]
  15. Green C. J., Allison A. C., Precious S. Induction of specific tolerance in rabbits by kidney allografting and short periods of cyclosporin-A treatment. Lancet. 1979 Jul 21;2(8134):123–125. doi: 10.1016/s0140-6736(79)90005-9. [DOI] [PubMed] [Google Scholar]
  16. Hughes W. T., Smith B. Provocation of infection due to Pneumocystis carinii by cyclosporin A. J Infect Dis. 1982 May;145(5):767–767. doi: 10.1093/infdis/145.2.767. [DOI] [PubMed] [Google Scholar]
  17. Kalman V. K., Klimpel G. R. Cyclosporin A inhibits the production of gamma interferon (IFN gamma), but does not inhibit production of virus-induced IFN alpha/beta. Cell Immunol. 1983 May;78(1):122–129. doi: 10.1016/0008-8749(83)90265-4. [DOI] [PubMed] [Google Scholar]
  18. Keown P. A., Essery G. L., Stiller C. R., Sinclair N. R., Mullen R., Ulan R. A. Mechanisms of immunosuppression by cyclosporin. Transplant Proc. 1981 Mar;13(1 Pt 1):386–389. [PubMed] [Google Scholar]
  19. Keown P. A., Stiller C. R., Ulan R. A., Sinclair N. R., Wall W. J., Carruthers G., Howson W. Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet. 1981 Mar 28;1(8222):686–689. doi: 10.1016/s0140-6736(81)91971-1. [DOI] [PubMed] [Google Scholar]
  20. Kirkland T. N., Fierer J. Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo. Antimicrob Agents Chemother. 1983 Dec;24(6):921–924. doi: 10.1128/aac.24.6.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Leapman S. B., Filo R. S., Smith E. J., Smith P. G. Differential effects of cyclosporin-A on lymphocyte subpopulations. Transplant Proc. 1981 Mar;13(1 Pt 1):405–409. [PubMed] [Google Scholar]
  22. Louria D. B., Kaminski T. Passively-acquired immunity in experimental cryptococcosis. Sabouraudia. 1965 Jun;4(2):80–84. doi: 10.1080/00362176685190211. [DOI] [PubMed] [Google Scholar]
  23. McNicholas J. M., Raffeld M., Loken M. R., Reiter H., Knight K. L. Monoclonal antibodies to rabbit lymphoid cells: preparation and characterization of a T-cell-specific antibody. Mol Immunol. 1981 Sep;18(9):815–822. doi: 10.1016/0161-5890(81)90003-1. [DOI] [PubMed] [Google Scholar]
  24. Miller G. P., Kohl S. Antibody-dependent leukocyte killing of Cryptococcus neoformans. J Immunol. 1983 Sep;131(3):1455–1459. [PubMed] [Google Scholar]
  25. Murphy J. W., McDaniel D. O. In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol. 1982 Apr;128(4):1577–1583. [PubMed] [Google Scholar]
  26. Murphy J. W., Moorhead J. W. Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol. 1982 Jan;128(1):276–283. [PubMed] [Google Scholar]
  27. Perfect J. R., Durack D. T. Chemotactic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Sabouraudia. 1985 Feb;23(1):37–45. doi: 10.1080/00362178585380071. [DOI] [PubMed] [Google Scholar]
  28. Perfect J. R., Lang S. D., Durack D. T. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol. 1980 Oct;101(1):177–194. [PMC free article] [PubMed] [Google Scholar]
  29. Perfect J. R., Lang S. D., Durack D. T. Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Pathol. 1981 Dec;62(6):595–599. [PMC free article] [PubMed] [Google Scholar]
  30. Peterson P. K., Ferguson R., Fryd D. S., Balfour H. H., Jr, Rynasiewicz J., Simmons R. L. Infectious diseases in hospitalized renal transplant recipients: a prospective study of a complex and evolving problem. Medicine (Baltimore) 1982 Nov;61(6):360–372. doi: 10.1097/00005792-198211000-00002. [DOI] [PubMed] [Google Scholar]
  31. Rook A. H., Masur H., Lane H. C., Frederick W., Kasahara T., Macher A. M., Djeu J. Y., Manischewitz J. F., Jackson L., Fauci A. S. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983 Jul;72(1):398–403. doi: 10.1172/JCI110981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schimpff S. C., Bennett J. E. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol. 1975 Jun;55(6):430–441. doi: 10.1016/0091-6749(75)90082-2. [DOI] [PubMed] [Google Scholar]
  33. Sweny P., Tidman N. The effect of cyclosporin A on peripheral blood T cell subpopulations in renal allografts. Clin Exp Immunol. 1982 Feb;47(2):445–448. [PMC free article] [PubMed] [Google Scholar]
  34. Thommen-Scott K. Antimalarial activity of cyclosporin A. Agents Actions. 1981 Dec;11(6-7):770–773. doi: 10.1007/BF01978803. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES